Boehringer Ingelheim said its experimental treatment for a chronic lung disease succeeded in a pivotal study, and it's taking ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it ...

The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...

Exposure to radiation from head or neck CT imaging increased risk for childhood brain tumors, according to results of a ...

Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

Discover how integrating advanced imaging, digital pathology, and molecular analysis, can refine fibrosis staging and ...

Share and Cite: Hinz, B. and Kenyon, J. (2025) Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...

Marking Rheumatoid Arthritis Awareness Day 2025 on February 2, it's essential to shed light on the often-overlooked connection between RA and lung health. Can rheumatoid arthritis cause lung damage?

A 41-year-old man was evaluated for swelling in the ankles and syncope. CT of the chest showed bilateral mediastinal and ...